NFKB1 and chronic kidney disease: Based on this evidence, we demonstrated that SQP may inhibit cellular senescence and senescence-associated inflammation by regulating the SIRT1/NF-κB pathway, and effectively treating CKD and OA using the homotherapeutic approach (Figure 10).